International Cancer Cluster Showcase 2018

Monday, June 4, 2018; 11:30 a.m. – 4:30 p.m.
Boston Convention Center, Level 2, Rooms 256 & 258A

Sponsored by:

11:30 – 12:30 p.m.	**REGISTRATION AND LIGHT LUNCH with POSTER SESSION**
12:30 – 12:45 p.m.	**Opening and Welcome by ICCS Organizing Partners and Sponsors** Welcome Notes: Allison Hilton, Senior Advisor, Healthcare Corporate Banking, DNB Healthcare and Pat Devitt, President, Precision Oncology
12:45 – 1:15 p.m.	**Company Pitches – I** Immunovaccine Alligator Bioscience Avvinity Therapeutics Third Coast Therapeutics OncoImmunity Leuko Labs
1:15 – 1:25 p.m.	**Boehringer Ingelheim Presentation** Scott DeWire, Global Head of BD&L Cancer Immunology, Immune Modulation and Biotherapeutics
1:25 – 1:50 p.m.	**Company Pitches – II** Amal Therapeutics TYG Oncology Ultimovacs CytoSavvy IPD Discovery Pharma MIMS
1:50 – 2:15 p.m.	**NETWORKING BREAK & POSTER SESSION**
2:15 – 2:20 p.m.	**Takeda Oncology Presentation** Natalie Roy D'Amore, Director, Takeda Oncology Drug Discovery
2:20 – 2:50 p.m.	**Company Pitches – III** Bessor Pharma Erytech MBF Therapeutics Immune Biosolutions Simplicity Bio Aiforia
2:50 – 3:00 p.m.	**Angel Group – Oncology Focus**
3:00 – 3:30 p.m.	**Company Pitches – IV** ABIVAX F-Star ASCIL Biopharm Phi Pharma Context Therapeutics StemTek
3:30 – 3:35 p.m.	**Closing Remarks**
3:35 – 4:30 p.m.	**NETWORKING RECEPTION & POSTER SESSION**

www.internationalcancercluster.org

Presenting Companies - International Cancer Cluster Showcase 2018

Immunovaccine Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Immunovaccine is pioneering a new class of immunotherapies based on the Company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. Immunovaccine's lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the platform with a target: survivin. Immunovaccine is currently conducting three Phase 2 studies with Incyte and Merck to assess DPX-Survivac as a combination therapy in ovarian cancer and diffuse large B-cell lymphoma.
Contact: Frederic Ors, CEO, +1 (902) 492-1819, fors@imvaccine.com
www.imvaccine.com

Alligator Bioscience discovers and develops mono- and bispecific antibody-based pharmaceuticals for cancer immunotherapy. The company specializes in the development of tumor-directed immunotherapies, i.e. drugs designed to localize the pharmacological effect to the tumor environment, resulting in an advantageous efficacy and safety profile. Alligator has a broad project portfolio comprising mono- and bispecific antibodies, all with first-in-class or best-in-class potential. These projects are in various stages of research, pre-clinical and clinical development. Examples of Alligator´s pipeline programs are: ADC-1013, a CD40 agonist antibody in phase I development, out-licensed to Janssen Biotech; ATOR-1015, a first-in-class CTLA-OX40 bispecific antibody planned to start phase I development 2018; and ATOR-1017, a 4-1BB agonist antibody designed to have best-in-class properties in terms of safety/efficacy profile. Alligator was founded in 2001 and is located at Medicon Village in Lund, Sweden. The company is listed on Nasdaq Stockholm.
Contact: Eva Dahlén, Senior Director Business Development, +46 73 6836750, evd@alligatorbioscience.com
www.alligatorbioscience.com

Avvinity Therapeutics ("Avvinity") is an immuno-oncology joint venture which is developing novel therapeutics called Alphamers that specifically target the cancer cell by binding to over-expressed or differentially-expressed surface proteins. Avvinity's Alphamers have demonstrated strong natural antibody polyclonal responses induced to both solid tumor and hematological tumors. They have the potential to be excellent combination partners for checkpoint inhibitors with significant advantages over standard antibody or antibody drug conjugate approaches. Our technology targets patients with tumors overexpressing EGFR and resistant to current targeted therapies. Avvinity is looking for investors and/or partners to facilitate taking their promising lead drug candidates into clinical development.
Contact: Jennifer Schneider, CEO, +1-574-210-7468, Jennifer.schneider@centauritherapeutics.com
www.avvinity.com and www.centauritherapeutics.com

Third Coast Therapeutics discovers and develops therapies designed to attack the metastatic process. There are currently no drugs approved to prevent the movement of cancer cells and theoretically, these anti-metastatics could improve outcomes of all treatment modalities. Third Coast has discovered a precise method to alter the activity of the co-chaperone complex which in turn alters the activity of key downstream client proteins. The lead drug candidate, 3crx98, is a highly precise small molecule that alters the activity of 3 key client kinases from a protein pool of hundreds. To date, 3crx98 has shown inhibition of 4 cancers and 15 cancer cell lines and has shown anti-metastatic activity in vivo in 3 cancers, with no significant adverse events. 3crx98 is advancing through pre-clinical testing required for an Investigational New Drug (IND) application submission.
Contact: Joseph Luminiello, CEO**,** Joe@3crx.com
www.3crx.com

OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy. One of the company's product offerings, the Immune-Profiler, is a machine-learning engine that predicts antigens that are processed and presented to the tumor cell surface, and therefore potentially immunogenic. OncoImmunity is dedicated to developing software solutions that facilitate effective patient selection for cancer immunotherapy, and identifying optimal targets for truly personalized cancer vaccines and cell therapies in a clinically actionable timeframe.
Contact: Richard Stratford, CEO, +47 900 15 242, richard@oncoimmunity.com
www.oncoimmunity.com

Leuko is developing the first medical device to non-invasively assess white blood cell (WBC) status and WBC differential. Assessment of WBC is necessary for the management of various medical conditions, such as the treatment of cancer with cytotoxic chemotherapy and serious infections with anti-infectives. There have been no advances in the assessment of WBCs in decades. We have re-imagined WBC testing without the need for blood draws by means of a mobile phone-sized portable device utilizing innovative optics. The initial focus will be on the hematology – oncology market in the U.S. Once proof-of-concept and the value of our technology is demonstrated in patients with cancer, additional opportunities will be explored.
Contact: Carlos Castro-Gonzalez, CEO, +1 617 952 1827, carlos@leuko.io
www.leuko.io

AMAL Therapeutics SA is a spin-off from the University of Geneva that is active in cancer immunotherapy. AMAL has developed a unique protein-based immunization platform called KISIMA® that activates signals to dendritic cells, simultaneously priming both helper and killer cells for various antigens and HLA restrictions. This first-in-class platform offers the opportunity to develop standardized and indication-tailored active immunotherapies. The company's lead product ATP128 is currently being developed for metastatic and advanced colorectal cancer. The manufacturability of the compound has been established, and currently process development and scale-up is ongoing. GLP toxicology studies will start in Q4 2018, and the initiation of the clinical trial in combination with an immune-checkpoint inhibitor is planned for Q3 2019.
Contact: Madhia Derouazi, CEO; +41 22 379 46 88, madiha.derouazi@amaltherapeutics.com
www.amaltherapeutics.com

TYG Oncology is developing first-in-class therapies using a technology platform to upgrade approved monoclonal antibody therapies to a natural polyclonal antibody produced by our bodies' own immune system, safely under Active Checkpoint Control. Our first product, TYG100, targets pancreatic cancer, and is designed to neutralize gastrin hormones G17 and G17-Gly, known growth and risk factors for gastrointestinal cancers. Our second product TYG200 is designed to trigger ADCC, CDC and cytotoxic T cell killing simultaneously. Designed to be well tolerated and administered outside of the hospital, TYG200 is ready for GMP manufacture. After TYG200 our packed pipeline includes plans to replace almost every existing approved monoclonal antibody therapy, including Humira, Avastin and Remicade. The company is seeking investors.
Contact: Fred Jacobs, CEO, +44 7989 386326, fred.jacobs@tyg-oncology.com
www.tyg-oncology.com

Ultimovacs' lead product UV1 is a therapeutic cancer vaccine directed against human telomerase (hTERT). The vaccine can provide a platform for other immuno-oncology drugs that require an ongoing T cell response for their mode of action. Clinical trials in prostate, NSCLC and Melanoma have been performed, the latter combining UV1 with ipilimumab. A clinical trial combining UV1 and pembrolizumab has just been initiated in the US.
Contact: Audun Tornes, COO, +47 9951 0951, Audun.Tornes@Ultimovacs.com
www.ultimovacs.com

CytoSavvy: The FDA's decision in 2017 to allow digital imagery from whole slide scanners to become a primary diagnostic tool has created a large-scale data mining problem for insurance companies, hospitals, and big pharma. Right now, millions of digital images across the country are not being analyzed because of a lack of appropriate tools and expertise. CytoSavvy's unique patented Shape Based Modeling Segmentation (SBMS) platform combines the production of hard data associated with clinical pathology images with the significantly improved accuracy of deep learning systems to provide a powerful new solution and set of tools to address overfitting and the bias-variance tradeoff (which frequently result in accuracy rates of less than 60% vs. over 95% for CytoSavvy). We are targeting high volume drug discovery and cancer grading applications currently performed 100% manually. Our competitive differentiator is reliability.
Contact: John Freyhof, CEO, +1 610-225-0498, john@cytosavvy.com
www.cytosavvy.com

IDP Discovery Pharma is a drug discovery company that develops first-in-class medicines (new chemical entities) directed to a novel class of therapeutic targets, intrinsically disordered transcription factors. We are currently focused on exploiting new mechanisms of action to treat both solid and liquid tumors. Our technology has demonstrated its capability to target two holy grails in cancer, cMYC and MASH-1 transcription factors. IDP Pharma exploits peptidomimetic technology to target up to now untapped therapeutic targets by the pharmaceutical industry. Our lead compounds are under preclinical development.
Contact: Santiago Esteban Martin, CEO, +34 600757648, s.esteban@idp-pharma.com
www.idp-pharma.com

MIMs: Genomics has been used for the past 20 years in research institutes, to understand the origin of life and diseases. MIMs has created MIMsOmic technology to allow life-scientists to transform data into actionable knowledge on their own. MIMsOmic's platform is built around an information technology system that employs Artificial Intelligence, and more particularly a goal-oriented massive multiagent system. With MIMsOmic, life scientists can work with OMIC data without relying on bioinformaticians or data scientists, for a fraction of the actual cost of existing operations and 4 to 5 times faster.
Contact: Sarah Jenna, Co-founder & CEO, sarah@mims.ai
www.mims.ai

Bessor Pharma has developed and is considering strategic alliance partners for a potential 1st in class, biomarker driven therapy for hard to treat cancers. We have discovered a new promising cancer target, the secreted protein renalase. Renalase is overexpressed in tumors and biological fluids of cancer patients and increased expression correlates with worse patient outcomes. Renalase knockouts block cancer development. Our drug candidate is a selective, anti-renalase mAb, which we are developing with Dr. Gary Desir, chair of medicine at Yale. With a top R and D and business team we translate opportunities from universities for the biopharma industry with a focus on immuno-oncology and immuno-inflammation.
Contact: Barry A. Berkowitz, Founder and CEO, bberkowitz@bessorpharma.com, 508-877-4522
www.bessorpharma.com

ERYTECH is developing cancer therapeutics based on a proprietary technology platform that encapsulates compounds in red blood cells. Our lead program, eryaspase (GRASPA®) encapsulates asparaginase in donor red blood cells, to treat solid and liquid tumors by acting on "tumor starvation" pathways while increasing the duration of efficacy and significantly reducing the toxicity profile. Erytech recently announced positive Phase IIb data in metastatic pancreatic cancer (PDAC) and is planning to initiate a global Phase III trial in Q3 2018. The Company is also expecting to initiate a Phase IIb trial in triple negative breast cancer (TNBC) in Q3 2018, and are awaiting CHMP feedback of the MAA resubmission of GRASPA® for Acute Lymphoblastic Leukemia (ALL) in late 2018. The company has licensing and distribution partnership agreements with Orphan Europe (Recordati Group) in Europe, and with TEVA in Israel for the commercialization of GRASPA in ALL and Acute Myeloid Leukemia.
Contact: Jean-Sebastien (JS) Cleiftie, CBO, js.cleiftie@erytech.com,
www.erytech.com

MBFT is a clinical-stage animal health company developing and commercializing proprietary check-point inhibitor immuno-therapy technology based on vaccines and vaccine adjuvants. This is a platform technology, licensed exclusively from the Wistar Institute, from which multiple innovative products can be developed for markets worth more than $5B. Our lead product is MBFT-201, a canine melanoma vaccine for dogs with Stage II/III resectable disease. We have completed a Phase I study that demonstrated the safety of our adenoviral-vectored product and elicited a strong immune response to the key antigens in 100% of the dogs treated. Based upon Dr. Hildegund Ertl's work (Caspar Wistar Professor in Vaccine Research), we foresee additional opportunities to develop products for the emerging infectious disease vaccine market that is responding to increased government restrictions and growing consumer objections to the use of antibiotics in animals.
Contact: Tom Tillett, ttillett@mbftherapeutics.com
www.mbftherapeutics.com

Immune Biosolutions, a JLabs@Toronto resident, is focusing on the discovery and engineering of humanized chicken antibodies targeting intractable membrane proteins with a recognized, yet unexploited, therapeutic potential. Membrane proteins are notoriously difficult targets for antibody discovery. IBio's Nebula Discovery Platform integrates four families of technology addressing historical bottlenecks:
1) Spatial Peptides: rationally designed synthetic peptides that replicate the native 3D structure of targets; 2) Chicken antibodies as a novel source of therapeutics, to circumvent the tolerance effect of highly conserved mammalian proteins; 3) Phage display technologies combined with next-generation sequencing to explore the full diversity of our antibody libraries and to select the best binders; and 4) Evolutive humanization technologies to engineer perfect immunotherapy agents. IBio is advancing two of its functional anti-GPCR antibody candidates in oncology, as well as the co-development of new therapeutics with industry leaders.
Contact: Frédéric Leduc, CEO, 1-855-346-3449, fleduc@ibiosolutions.com
www.immunebiosolutions.com

SimplicityBio serves life sciences companies in their translational efforts. Its machine learning platform BOSS - Biomarker Optimization Software System turns data streams (omics, clinical, RWE, etc) into robust tailored models revealing new pathways, drug targets and biomarkers. Drug-disease interactions are complex and single markers have low clinical relevance. BOSS uses multiple biomarkers and human-readable rules to discover robust models and quantify uncertainty beyond confidence intervals. The software platform provides value to our clients from discovery to clinical validation by creating clinically relevant models for patient stratification and diagnosis, predicting activity, efficacy, treatment resistance, etc.
Contact: Matthew Hall**,** CEO and Co-founder; +41 76 241 03 25, info@simplicitybio.com
www.simplicitybio.com/

AIFORIA is a software company specialized in developing intelligent, cloud-based image analysis solutions for digital pathology. Aiforia™'s technology brings together Deep Learning -based Image Analysis and high-performance Cloud Computing. Our SaaS solutions enable fast, accurate, and affordable analysis support for pathologists and medical researchers requiring tissue-based image analytics. New algorithms are available on-demand or with a novel self-service model, where users are able to create their own deep learning algorithms using our browser-based interface.
Contact: Thomas Westerling-Bui, Senior Scientist & Regional Business Development, +1-617-943-9971, Thomas.Westerling@fimmic.com
www.aiforia.com

ABIVAX is harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory diseases and cancer. From its immune enhancement platform, ABIVAX is currently developing ABX196, a state of the art immune enhancer candidate based on iNKT activation. A phase I clinical trial has been completed and showed activation of iNKT as well as a stimulation of an immune response. Based on these encouraging data, new immuno-oncology pre-clinical studies have been conducted showing that ABX196 enhances anti-tumoral activity in combination with an anti-PD-1 antibody, doxorubicin or sorafenib. Following the highly statistically significant preclinical results, a US phase I/II study of ABX196 in combination with anti-PD1 in patients with Hepatocellular Carcinoma (HCC) is scheduled Q4 2018.
Contact: Hartmut Ehrlich, Prof., CEO, +33 (0)1 5383 0841, Hartmut.Ehrlich@abivax.com
www.abivax.com

F-star is a clinical-stage biotech developing immuno-oncology bispecific antibody therapeutics with high potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star can rapidly create bispecific antibodies with properties virtually identical to normal antibody. This offers unprecedented ease in the discovery, development, and manufacturing of bispecific antibody products. F-star's management team has a well-established track record in building successful biotech companies and developing biologics. Partnerships have been created with leading biopharmaceutical companies including AbbVie, Merck and Denali Therapeutics. F-star has raised close to $200M in non-dilutive capital and revenues. The company currently employs over 90 people at its research site in Cambridge, UK.
Contact: Jane Dancer, CBO, +44 1223 497400, jane.dancer@f-star.com
www.f-star.com

ASCIL BIOPHARM: Somatostatin analogues (SSAs) are the gold standards of care for first line systemic therapy of advanced neuroendocrine tumors (NETs) and long-acting SSAs are widely used in long-term therapies of NETs. However, there is increasing evidence that clinical benefits could be obtained with higher SSA circulating levels that are unreachable with current products. APOC is a new injectable controlled release treatment containing octreotide developed by Ascil Biopharm and designed to cover specifically these clinical unmet needs with improved product presentation and performance. APOC allows personalized treatment at selected doses and durations. APOC is currently under clinical evaluation and Ascil is seeking for partner for next stage of development.
Contact: Laurence Lachamp, Business Innovation Director and Co-founder, +34 934 137 922, busdev@ascil-biopharm.com
www.ascil-biopharm.com

Phi Pharma SA is a private Swiss biopharmaceutical company focused on peptide drug conjugates as cancer therapeutics. The Phi Pharma platform allows development of a powerful new class of drug conjugates through specific cellular targeting and efficient delivery of therapeutics inside cancer cells. Using targeting peptides rather than antibodies provides a number of advantages:

- small size that can penetrate the tumor quickly
- relatively short time in the blood stream to minimize potential toxicity
- can be chemically synthesized: lower costs of development and of manufacturing
- a wider variety of active drugs can be delivered

Contact: Tom Shepherd, Chief Executive Officer, +41 77 954 13 77, tom.shepherd@phi-pharma.com
www.phi-pharma.com

Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context's lead program is Apristor (Onapristone XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. Apristor is an NCE with patent protection through at least 2034. In addition, Context is advancing CTX-030916, a potential best-in-class oral antiprogestin for the treatment of uterine fibroids and endometriosis, and a discovery-stage program targeting Sigma1.
Contact: Martin Lehr, CEO, +484 451 8601, info@contexttherapeutics.com
www.contexttherapeutics.com

StemTek has developed a ready-to-use cell culture technology that maintains the natural architecture of the tumor in 3D and replicates the in vivo structure more closely than traditional cell culture. The company's innovation, an all in one kit drastically reduces the time to produce research results by eliminating sample prep. StemTek is also applying this technology to personalize the development and use of cancer medicines to predict the best treatment course by developing the patient's own 3D tumor model to test available treatments and investigational new drugs. StemTek has set up a consortium of 3 leading hospitals in oncology to validate this solution.
Contact: Angel Garcia Martin, CEO, (+1) 240-447-4478
www.stemtektherapeutics.com

Organizing Partners International Cancer Cluster Showcase 2018

Massachusetts Technology Transfer Center - Massachusetts' unique ecosystem of leading research institutions, supporting organizations, and investor community spurs the creation of numerous new companies every year. Massachusetts' cancer expertise is maintained by cutting edge research at multiple institutions including the Dana-Farber Cancer Institute and the David Koch Institute for Integrative Cancer Research at MIT. Many of the newly formed companies in the Commonwealth focus on cancer diagnostics and treatment. The Massachusetts Technology Transfer Center is a non-profit organization that supports technology transfer activities from public and private research institutions to companies in Massachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.
Contacts: Abigail Barrow, abarrow@umassp.edu; Christa Bleyleben, cbleyleben@massglobalpartners.com; www.mttc.org

The Oncopole brings together various stakeholders to work on this structuring project. This partnership is a unique co-creation with an inclusive idea development and implementation process which involved over 50 experts from the scientific community collaborating over the past year to identify its priorities. Recognizing the range of resources and infrastructures currently available as well as the strategic positioning of many researchers here in Québec, this project will strengthen, to the patient's benefit, the research and innovation ecosystem.
The Oncopole mobilizes the community around a shared vision:
to create a flagship hub in oncology, internationally recognized for its cohesiveness, effectiveness and avant-garde approach;
to enable the incubation and creation of companies that will capitalize on innovation;
to generate direct positive benefits for patients;
to position cancer care in Québec among the best in the world in terms of clinical outcome, patient experience and system efficiency.
Contact: Richard Cloutier, Richard.cloutier@reseaubio-innovation.com; www.oncopole.ca

The Wistar Institute is the nation's first independent institution devoted to medical research and training. The Wistar Institute has evolved from its beginnings as an anatomical teaching museum to its present-day status as an international leader in basic biomedical research. In 1972, The Wistar Institute was designated a National Cancer Institute Cancer Center in basic research, a distinction it holds to this day. Wistar discoveries have led to the development of vaccines for rabies, rubella, and rotavirus, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.
Contact: Heather Steinman, HSteinman@Wistar.org; www.wistar.org

Oslo Cancer Cluster is an oncology focused research and industry cluster. Organized as non-profit member organization Oslo Cancer Cluster is dedicated to accelerate the development of new cancer treatments. The 90 members represent the entire R&D value chain and include academic research institutes, university hospitals, biotechs, investors, and international Pharma companies. The cluster's growing pipeline comprises innovative therapeutics and diagnostics including novel cancer immunotherapies in preclinical and clinical development. Around 35 of the members are gathered in the Oslo Cancer Cluster Incubator, situated in the Oslo Cancer Cluster Innovation Park. We share the innovation park with Ullern Upper Secondary School, the Cancer Registry of Norway and Oslo University Hospital.
Contact: Jutta Heix, jh@oslocancercluster.no; www.oslocancercluster.no

OBN is the Membership organization supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. Our 360-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland benefiting from our networking, partnering, purchasing, advising and advocacy activities.
Contact: john.harris@obn.org.uk; www.obn.org.uk

Medicen is the competitiveness cluster of the Paris Region and one of Europe's largest cluster in Life Sciences and Healthcare. Founded in 2005, it offers a unique forum connecting all the key stakeholders: leading research institutes, innovative SMEs, hospitals, incubators, large companies and territorial authorities. Medicen goal is to increase the attractiveness of the Paris region, strengthen the international competitiveness of the health sector and develop the economic growth of its members in strategic markets through collaborative innovation. With 300 members and more than 200 innovative SMEs, Medicen is a unique gateway to innovate with Paris Region actors. Medicen is structured around 5 major technological areas:

- In vitro diagnostics
- Diagnostic and interventional imaging systems
- Regenerative Medicine and biomaterials
- ICT for Health
- Translational medicine

Contact: Olivier Fontaine, ofontaine@medicen.org; www.medicen.org

Biocat acts as a strategic agent and catalyst in the construction of the Catalan healthcare and life sciences ecosystem. Its mission is to establish liasons between all the stakeholders of the BioRegion (companies, research groups and entities, hospitals and innovation support structures) to transform knowledge and technology into economic growth and to create a social impact. Biocat was created in 2006 at the behest of the Government of Catalonia and the Barcelona City Council to provide a joint strategy for the Catalan biosciences sector as the foundation of a new economy based on knowledge and innovation. www.biocat.cat/en

Contact: Roy Villar, Head of Internationalization, rvillar@biocat.cat

Biopôle is a unique life sciences park hosting a vibrant community of world-renowned industry players and research institutes, based in Lausanne (Switzerland) at the heart of the Swiss Health Valley. Biopôle offers a world-class combination of modern infrastructure, added value services, a life sciences incubator StartLab, over 134,000 sqm/1,440,000 sqft of living space and community engagement where all partners can thrive and bring science to life. While it is open to all therapeutic areas, the main focus of Biopôle is on developing innovative solutions in the fields of oncology, immunology and personalized medicine. These solutions can cover a wide spectrum, from diagnostics to therapeutics, medical devices, nutrition and digital health. Biopôle works with both industry and academia to ensure that there is communal knowledge and appreciation of what projects they are pursuing and where there might be opportunities for synergies and collaboration.

Contact: Olivier Philippe, Director of Business Development & Corporate Relations, olivier.philippe@biopole.ch, www.biopole.ch

The Chicago Cancer Cluster is a consortium that was created since 2013, bringing together the cancer centers from the 3 major Chicago Universities (Northwestern University, University of Chicago and University of Illinois in Chicago). The Robert H. Lurie Comprehensive Cancer Center of Northwestern University dedicated to discovery, advancing medical knowledge, providing compassionate, state-of-the-art cancer care, and training the next generation of clinicians and scientists while being an NCI-designated comprehensive cancer centers in Illinois—one of only 40 such centers in the country. The Cancer Center of UIC plays a unique role in the Chicago area by its commitment and ability to reach out to underserved populations of Illinois, including both urban minority and rural populations, and its commitment as a state institution to serve as a major statewide resource for cancer research and care. With its links to regional medical campuses, at Rockford, Peoria, and Urbana, the UIC Cancer Center has developed a statewide network of excellence in cancer research and care. At the University of Chicago Medicine Comprehensive cancer from every angle. The UCCCC is recognized by the National Cancer Institute (NCI) as a preeminent leader in research to prevent cancer, elucidate its complexities, and develop novel therapies for state-of-the-art patient care. The Chicago Cancer Cluster convenes every year for the ICCS meeting during BIO and it is one of the many ways that the Chicago Universities collaborate, including being part of the Chicago Biomedical Consortium.

For more information please see cancer.northwestern.edu & chicago.medicine.uic.edu/cancercenter & cancer.uchicago.edu

Special thanks to the ICCS2018 Sponsors: